Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia
Circulation · 19.03.2024 · 149 (12) · 944-962
DOI: 10.1161/circulationaha.122.062952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 19.03.2024. Verfasst von Gael Genet und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology (G.G., N.G., U.P., S.R.C., A.C., S.P.M., D.S., M.H., E.A.N., K.K.H.), School of Medicine, University of Virginia, Charlott…. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Arteriovenous Malformations. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NHLBI NIH HHS, American Heart Association-American Stroke Association.
Abstract (Originalsprache)
BACKGROUND: Distinct endothelial cell cycle states (early G1 versus late G1) provide different “windows of opportunity” to enable the differential expression of genes that regulate venous versus arterial specification, respectively. Endothelial cell cycle control and arteriovenous identities are disrupted in vascular malformations including arteriovenous shunts, the hallmark of hereditary hemorrhagic telangiectasia (HHT). To date, the mechanistic link between endothelial cell cycle regulation and the development of arteriovenous malformations (AVMs) in HHT is not known. METHODS: We used BMP (bone morphogenetic protein) 9/10 blocking antibodies and endothelial-specific deletion of activin A receptor like type 1 ( Alk1 ) to induce HHT in Fucci (fluorescent ubiquitination-based cell cycle indicator) 2 mice to assess endothelial cell cycle states in AVMs. We also assessed the therapeutic potential of inducing endothelial cell cycle G1 state in HHT to prevent AVMs by repurposing the Food and Drug Administration–approved CDK (cyclin-dependent kinase) 4/6 inhibitor (CDK4/6i) palbociclib. RESULTS: We found that endothelial cell cycle state and associated gene expressions are dysregulated during the pathogenesis of vascular malformations in HHT. We also showed that palbociclib treatment prevented AVM development induced by BMP9/10 inhibition and Alk1 genetic deletion. Mechanistically, endothelial cell late G1 state induced by palbociclib modulates the expression of genes regulating arteriovenous identity, endothelial cell migration, metabolism, and VEGF-A (vascular endothelial growth factor A) and BMP9 signaling that collectively contribute to the prevention of vascular malformations. CONCLUSIONS: This study provides new insights into molecular mechanisms leading to HHT by defining how endothelial cell cycle is dysregulated in AVMs because of BMP9/10 and Alk1 signaling deficiencies, and how restoration of endothelial cell cycle control may be used to treat AVMs in patients with HHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology (G.G., N.G., U.P., S.R.C., A.C., S.P.M., D.S., M.H., E.A.N., K.K.H.), School of Medicine, University of Virginia, Charlottesville.
- Robert M. Berne Cardiovascular Research Center (N.W.C., V.S., K.K.H.), School of Medicine, University of Virginia, Charlottesville.
- Program Against Cancer Therapeutic Resistance, Institut Catala d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain (A.F.).
- Oncobell Program (A.F.), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- (P.C., A.R.-M.), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- HHT Unit, Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain (P.C., A.R.-M.).
ORCID-Profile: Gael Genet, Nafiisha Genet, Umadevi Paila, Shelby R Cain, Aleksandra Cwiek, Nicholas W Chavkin, Vlad Serbulea, Pau Cerdà, Mahalia Huba, Antoni Riera-Mestre, Karen K Hirschi
Förderung
- NIBIB NIH HHS
- NHLBI NIH HHS
- American Heart Association-American Stroke Association
Zitieren
APA
Genet, G., Genet, N., Paila, U., Cain, S. R., Cwiek, A., Chavkin, N. W., Serbulea, V., Figueras, A., Cerdà, P., McDonnell, S. P., Sankaranarayanan, D., Huba, M., Nelson, E. A., Riera-Mestre, A., & Hirschi, K. K. (2024). Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. Circulation, 149(12), 944-962. https://doi.org/10.1161/circulationaha.122.062952
Vancouver
Genet G, Genet N, Paila U, Cain SR, Cwiek A, Chavkin NW, et al. Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. Circulation. 2024;149(12):944-962. doi:10.1161/circulationaha.122.062952
BibTeX
@article{Genet2024,
author = {Genet, Gael and Genet, Nafiisha and Paila, Umadevi and Cain, Shelby R and Cwiek, Aleksandra and Chavkin, Nicholas W and Serbulea, Vlad and Figueras, Agnès and Cerdà, Pau and McDonnell, Stephanie P and Sankaranarayanan, Danya and Huba, Mahalia and Nelson, Elizabeth A and Riera-Mestre, Antoni and Hirschi, Karen K},
title = {Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia},
journal = {Circulation},
year = {2024},
volume = {149},
number = {12},
pages = {944--962},
doi = {10.1161/circulationaha.122.062952}
}
EUVIMED